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Abstract 
Although miRNA markers have been identified for the pathological development of gastric 
adenocarcinoma (GAC), the underlying molecule mechanism are still not fully understood. Moreover, 
some gastric adenoma/dysplasia may progress to GAC. In this study, the miRNA expression profiles in 
normal and paired low-/high-grade dysplasia were analyzed using Affymetrix Gene-Chip miRNA arrays. 
Of the total 2578 mature miRNA probe sets, ~1600 showed positive signals when the between normal 
and paired low-/high-grade dysplasia were compared. To verify the miRNA expression, qRT-PCR analysis 
was performed to quantify the expression of altered miRNAs between normal and paired 
low-/high-grade dysplasia. The analysis revealed that hsa-miR-421, hsa-miR-29b-1-5p, and 
hsa-miR-27b-5p were overexpressed in gastric low-/high-grade dysplasia and that based on these 
miRNA-target interactions, FBXO11 and CREBZF could be considered convincing markers for gastric 
cancer (GC) progression. Thus, we identified three miRNAs (hsa-miR-421, hsa-miR-29b-1-5p, and 
hsa-miR-27b-5p) with two mRNAs (FBXO11 and CREBZF) that might play an important role in the GC 
development from premalignant adenomas. Furthermore, these two target mRNAs and three miRNAs 
were predicted to be potential biomarkers for the progression of GC by miRNA-target interaction 
analysis. 
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Introduction 
Gastric cancer (GC) is one of the most common 
cancer types in the world. It is the fourth most 
common malignancy and the third leading cause of 
cancer mortality around the world [1-3]. Gastric 
adenomas may eventually develop into adeno-
carcinoma, which are the most common type of GCs; 
gastric adenocarcinoma (GAC) accounts for over 90% 
cases of all GC [2,3]. Previous studies have strongly 
suggested that high-grade dysplasia is highly 
predictive of invasive carcinoma, while the clinical 
significance of low-grade dysplasia is still unknown 
[4-7]. Several groups have studied adenomas as the 
intermediate step of gastric carcinoma development 
[2,8]. Moreover, numerous studies have identified 
oncogenes and tumor suppressor genes involved in 
the pathological development of GAC. However, the 
mechanism of genes is still not fully understood. 
Small RNA molecules (19–23 nucleotide long) 
are also involved in tumor progression. MicroRNAs 
(miRNAs) are endogenous, non-coding single- 
stranded RNAs that play critical roles in the 








miRNAs function as posttranscriptional gene 
regulators by binding to their target mRNAs [9,10]. 
Altered miRNA expression has been observed in 
various kinds of cancer, including breast cancer, 
hepatocellular carcinoma, colorectal cancer, and lung 
cancer [11-14]. Aberrant expression of miRNAs is 
associated with GAC development, and analyses of 
multiple parallel gene expression alterations are 
providing deeper insights into oncogenic 
transformation [15,16]. Therefore, different miRNAs 
might be involved in different pathological processes, 
and these miRNAs act as prognostic markers for 
cancer progression. miRNAs are considered as 
potential risk factors and are associated with an 
increased risk of cancer. They also pay a role in the 
formation and progression of GC but less is known 
about their role in premalignant adenomas. 
Changes in the expression pattern of miRNAs 
can be informative and highly significant in the 
gastric adenoma-carcinoma sequence progression as 
well. However, precancerous tissues (such as 
dysplasia/adenoma) have been investigated less 
frequently than cancerous tissues [17-19]. The 
molecular characteristics of adenoma, especially of 
biopsy specimens, have not been fully elucidated. 
The aim of the present study was to perform a 
miRNA microarray analysis of normal, low-grade, 
and high-grade dysplasia using fresh frozen tissues. 
Changes in miRNA expression patterns, in samples 
obtained from the same patients, were also verified 
using TaqMan MicroRNA Assays. 
Materials and Methods 
Clinical samples and tissue harvesting 
Human tissue samples were obtained from 17 
patients who underwent endoscopic submucosal 
dissection (ESD) at the Severance Hospital of Yonsei 
University. The study protocol was approved by the 
ethics review committee of the Institutional Review 
Board, College of Medicine, Yonsei University. 
Among these, one patient was dropped from this 
study because no tumor was found in the ESD 
specimen, as well as seven patients whose RNAs 
samples did not meet quality control standards for 
miRNA analysis. The basic information of six patients 
(low-grade dysplasia, n=3 and high-grade dysplasia, 
n=3) is shown in Table 1. GAC was confirmed by 
histopathological examination of tumor tissues after 
physical resection. The histological examination was 
performed by experienced pathologists without 
authorship in this study. Tumor grade was 
determined by two tier WHO classification: low-grade 
or high- grade dysplasia. For GAC, differentiation 
(well, moderate, poorly differentiated or signet ring 
cell carcinoma), depth of invasion, and presence or 
absence of lymphovascular or neural invasion were 
recorded. 
 
Table 1. Clinicopathological features of 6 patients. 
Patient 
No. 
Gender Age  Histologic diagnosis  Helicobacter pylori 
status 
1 M 77 Low-grade dysplasia Positive  
2 M 74 Low-grade dysplasia Negative  
3 F 57 Low-grade dysplasia Positive  
4 M 58 High-grade dysplasia Negative  
5 M 61 High-grade dysplasia Negative  
6 M 61 High-grade dysplasia Positive  
 
Isolation and quality check of total RNA 
including miRNA 
Total RNA was extracted from 6 matched pairs 
of tissue samples (3 normal and 3 low grade dysplasia 
samples, 3 normal and 3 high-grade dysplasia 
samples) using the mirVana PARIS Kit (Ambion, 
USA) according to manufacturer's protocol. RNA 
purity and integrity were evaluated by ND-1000 
Spectrophotometer (NanoDrop, Wilmington, USA), 
and Agilent 2100 Bioanalyzer (Agilent Technologies, 
Palo Alto, USA). 
miRNA microarray 
The miRNA expression profiles were analyzed 
using the Affymetrix Gene-Chip miRNA 4.0 array 
(Homo sapiens). Total RNA (1 ug) including miRNA 
from tissue was biotin-labeled using the FlashTagTM 
Biotin HSR RNA Labeling kit (Affymetrix, 
Genisphere, Hatfield, PA, USA). The samples were 
hybridized using GeneChip® Hybridization Oven to 
the Affymetrix miRNA microarray according to the 
protocols provided by the manufacturer. The labeled 
RNA was heated to 99°C for 5 minutes and then to 
45°C for 5 minutes. RNA-array hybridization was 
performed with agitation at 60 rotations per minute 
for 16 hours at 48°C on an Affymetrix® 450 Fluidics 
Station. The chips were washed and stained using a 
Genechip Fluidics Station 450 (Affymetrix, Santa 
Clara, California, United States). The chips were then 
scanned with an Affymetrix GCS 3000 scanner 
(Affymetrix, Santa Clara, California, United States). 
Signal values were computed using the Affymetrix® 
GeneChip™ Command Console software. 
qRT-PCR 
The cDNA was reverse transcribed using 
TaqMan MicroRNA Reverse Transcription Kit 
(Applied Biosystems, Waltham, Massachusetts, USA). 
To determine miRNA expression levels, qRT-PCR 
was performed using TaqMan MicroRNA Assays 
(Applied Biosystems) according to the manufacturer's 




instruction. U6 snRNA was used as an internal 
control. 
In silico miRNA-mRNA target prediction 
Three miRNAs that were continuously 
up-regulated in adenoma progression (in normal vs. 
low-/high-grade adenoma) by TaqMan MicroRNA 
Assays were selected: hsa-miR-421, hsa-miR-29b-1-5p, 
and hsa-miR-27b-5p. Using miRNet web database 
(www.mirnet.ca/) we acquired pathway enrichment 
from gene ontology [20]. Using the KEGG pathway 
databases, we examined the pathway target 
enrichment (p<0.05) of selected groups of miRNAs. 
Statistical analysis 
Raw data were extracted automatically in 
Affymetrix data extraction protocol using the 
software provided by Affymetrix GeneChip® 
Command Console® Software (AGCC). The CEL files 
import, miRNA level RMA+DABG-All analysis and 
result export were performed using Affymetrix® 
Expression Console™ Software. Array data were 
filtered by probes annotated species. Comparative 
analysis was carried out between test and control 
samples using fold-change and independent T-test, in 
which the null hypothesis was that no difference 
exists among the 2 groups. False discovery rate (FDR) 
was controlled by adjusting the p value using 
Benjamini-Hochberg algorithm. All statistical tests 
and visualization of differentially expressed genes 
were conducted using R statistical language v. 3.1.2. 
Results 
Microarray analysis of miRNA expression in 
different patient groups 
First, the absolute number of expressed miRNAs 
in the analyzed sample groups (normal and 
low-/high-grade dysplasia from matched pair tissues) 
was determined based on the intensity values of 
oligonucleotide probes for 2578 human mature 
miRNAs that were synthesized on the surface of 
GeneChip miRNA 4.0 arrays. Present values (based 
on hybridization) were calculated with the Expression 
Console Software (Affymetrix) using the statistical 
present/absent calls method. Of the 2578 mature 
miRNA probe sets, ~1600 showed positive values in 
all tissue samples (Fig. 1). There were no significant 
differences in detection probes between the diagnostic 
groups. 
Discovery of expressed miRNA between 
normal and low-/high-grade dysplasia of 
patients 
Fig. 2A and Fig. 2C show heatmaps of 
microarray data describing the miRNA expression 
profiles in normal vs. low-/high-grade dysplasia of 
patients. The volcano plot graph of the miRNA array 
shows that log 2 of the fold change in the expression 
of each miRNA between normal and low-/high-grade 
dysplasia is versus its -log 10 of P value from the t-test 
(Fig. 2B and 2D). The vertical blue line indicates that 
the threshold of fold change in miRNA expression is 
≥1.5. The horizontal red line indicates that the 
threshold of P value of the t-test is 0.05. Up-regulated 
(red spots) and down-regulated (green spots) 
miRNAs which showed significantly different 
expression between control group and 
low-/high-grade dysplasia tissues (Fig. 3). 
miRNA microarray validation 
In order to confirm the accuracy and reliability of 
the microarray data, the same tissue/RNA samples 
used in miRNA microarray analysis were analyzed 
using TaqMan MicroRNA Assays. qRT-PCR 
validation was done on four tissue samples pooled 
(with equal ng of RNA of the samples in each group) 
according to the analyzed diagnostic groups (normal, 
low-grade dysplasia, and high-grade dysplasia). 
miRNAs showing altered expression in normal and 
low-/high-grade dysplasia in the microarrays were 
selected, and the expression tendencies 
were detected by qRT-PCR (Fig. 4A). 
Three miRNAs (hsa-miR-421, hsa-miR- 
29b-1-5p, hsa-miR-27b-5p) were identi-
fied to be consistently upregulated in 
pathological progression from normal 
to low-/high-grade dysplasia in the 
qRT-PCR results. 
miRNA-target interaction and 
biological function/pathway 
analysis 
Considering that miRNA can 
post-transcriptionally regulate the 
expression of target genes, we analyzed 
 
Figure 1. Number of miRNAs positive values from the mature miRNA probe sets in normal and 
low-/high-grade dysplasia on the Gene-Chip miRNA 4.0 array.  




the miRNA-target interacttions and functional 
association through network-based visual analysis 
(miRNet) (Fig. 4B and 4C). Herein, we identified that 
two mRNAs (FBXO11 and CREBZF) along with their 
corresponding miRNAs, which were significantly 
associated with GC progression. Therefore, three 
miRNAs (hsa-miR-421, hsa-miR-29b-1-5p, and 
hsa-miR-27b-5p) with two mRNAs (FBXO11 and 
CREBZF) might play an important role in the 
development of GC from premalignant adenomas. 
According to the results of the miRNet network 
analysis, two targets and three miRNAs were 
predicted as potential biomarkers for the progression 
of GC. Moreover, KEGG pathway enrichment 
analysis revealed that the miRNA-targets were 
significantly associated with pathways in cancer, 
colorectal cancer, and focal adhesion (Table 2). 
Discussion 
In this study, we have carried out a high 
throughput screening of microRNA expression 
alterations in normal and paired low-/high-grade 
dysplasia tissues using microarray analysis. We 
investigated the expression levels of 2578 mature 
miRNA in normal and low- and high-grade dysplasia 
tissues using GeneChip® miRNA 4.0 Arrays. Besides 
the previously described miRNAs between normal 
and gastric carcinoma lesions, we also identified new, 
lesser known miRNAs (hsa-miR-421, hsa-miR-29b- 
1-5p, and hsa-miR-27b-5p), with altered expression in 




Figure 2. Hierarchical clustering heat map showing differential miRNA expression in normal vs low-/high-grade dysplasia and volcano plot 
graph of miRNA array results. (A) and (B) for normal vs low-grade dysplasia; (C) and (D) for normal vs high-grade dysplasia. The vertical blue line indicates that 
the threshold for fold change in miRNA expression is ≥1.5. The horizontal red line indicates that the threshold p value of the t-test is 0.05. 





Figure 3. Differentially regulated miRNAs in tissues from normal group compared with low-grade dysplasia (A)/High-grade dysplasia (B).  
 
Table 2. Functional association of KEGG databases of the 
selected miRNAs-target interaction genes. 
Name Number of hit genes P value 
Pathways in cancer 11 5.14e-12 
Colorectal cancer 4 0.000256 
Focal adhesion  4 0.0177 
Progesterone-mediated oocyte maturation 3 0.0177 
Prostate cancer 3 0.0177 
Toxoplasmosis 3 0.0338 
FoxO signaling pathway 3 0.0419 
Wnt signaling pathway 3 0.0419 
Hepatitis B 3 0.0419 
PI3K-Akt signaling pathway 4 0.0423 
 
A previous study using deep sequencing 
analysis, found that hsa-miR-421 is differentially 
expressed and plays important roles in carcinogenesis 
in human GC [21]. Moreover, hsa-miR-421 was 
detected in serum, and this miRNA was suggested to 
be a novel class of biomarker for diagnosis of cancer 
and other diseases [22]. However, new findings from 
this study demonstrated that hsa-miR-29b-1-5p and 
hsa-miR-27b-5p might be overexpressed in GC 
progression from adenoma/dysplasia. Based on the 
prediction in miRNet network analysis, two targets, 
FBXO11 and CREBZF, were identified as potential 
biomarkers for the progression of GC. Functionally, 
FBXO11 encodes a member of the F-box protein 
family and PKD1 phosphorylation-dependent 
degradation of SNAIL in epithelial-mesenchymal 
transition (EMP) and metastasis [23]. Previous results 
have demonstrated that FBXO11 complex also 
mediates ubiquitination and degradation of DTL, an 
important step for the regulation of TGF-beta 
signaling, cell migration and the timing of the 
cell-cycle progression and exit [24,25]. Another 
predicted target CREBZF is a transcription factor that 
target was suggested as a novel positive regulator of 
p53 [26]. Previous research identified that CREBZF 
activates transcription when bound to HCFC1 and 
suppresses the expression of HSV proteins in cells 
infected with the virus in an HCFC1-dependent 
manner [27]. Furthermore, CREBZF suppresses the 
HCF1-dependent transcriptional activation by CREB3 
and reduces the amount of CREB3 in the cell [28]. 






Figure 4. Validation of miRNAs and miRNA-Target interaction. (A) Three miRNAs (miR-421, miR-29b-1-5p, miR-27b-5p) were selected as they were 
consistently up-regulated from normal to low-/high-grade dysplasia, (B) miRNA-target interactions and functional associations through network-based visual analysis, 
(C) miRNA-targets associated with pathways in cancer using KEGG pathway enrichment analysis. Significant differences between normal and low-/high-grade 
dysplasia were determined via ANOVA, with p values indicated as *p<0.05 and **p<0.01. 
 
Collectively, by integrating the results of miRNA 
expression alteration by GeneChip® miRNA 4.0 
Arrays with TaqMan RT-PCR from adenoma/ 
dysplasia, our data reveals that FBXO11 and CREBZF 
are closely related molecules for cancer development. 
Furthermore, correlation between miRNA expression 
and predicted target mRNA could be explored by 
functional analysis of GAC development related 
alterations, and this might serve as a valuable early 
diagnostic marker. 
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